A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Phase of Trial: Phase I
Latest Information Update: 24 May 2017
At a glance
- Drugs Ipafricept (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 17 May 2017 Planned End Date changed from 1 Apr 2017 to 1 May 2017.
- 17 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 May 2017.
- 08 May 2017 Status changed from active, no longer recruiting to suspended, according to an OncoMed Pharmaceuticals media release.